A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine
Clinical trial NCT05743335 · COMPLETED
Trial details
- NCT number
- NCT05743335
- Sponsor
- Immorna Biotherapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2023-03-07
- Primary completion
- 2023-12-01
- Enrollment
- 73
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.